Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

ALNYLAM PHARMACEUTICALS, INC.

Filed by TODD STRATEGY GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-01 06:26:09 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 19, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
06b8043b-fdcd-40f7-878c-3206cc573869
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act. Home infusion policy. Issues related to MFN drug pricing.

TRD · Trade (domestic/foreign)

Issues relating to supply chain tariffs.

PHA · Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94). Drug Pricing. FY2026 Labor HHS appropriations. Genetically targeted technologies. Policies related to medical innovation.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.